



Teva Pharmaceutical Industries Ltd.

Web Site: www.tevapharm.com

Contact: Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840
Bill Fletcher
President and CEO
Teva North America
(215) 591-8800
Dorit Meltzer
Director, Investor Relations
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7554

FOR IMMEDIATE RELEASE

**TEVA ANNOUNCES THIRD QUARTER GLOBAL IN-MARKET SALES OF
COPAXONE INCREASED 34% TO \$242 MILLION**

Jerusalem, Israel, October 21, 2004 – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of its partner Sanofi-Aventis Group's financial results, that global in-market sales of Copaxone® amounted to \$242 million in the third quarter ended September 30th, an increase of 34% over the comparable quarter of 2003.

U.S. sales increased 32% over the third quarter of 2003 to \$163 million. Sales outside the U.S, mainly in Europe, increased by 39%, to \$79 million.

During the first nine month period of 2004, global in-market sales of Copaxone® totaled \$675 million, an increase of 32% over the comparable period of 2003. U.S. in-market sales increased 28% to \$450 million and non US in-market sales increased 41% to \$224 million.

In the U.S., the world's largest MS market, Copaxone's total prescription share continued to build on the 30% milestone achieved in June, capturing 30.5% of the market's total prescriptions in the third quarter of 2004.

As previously announced, Teva will release its Third Quarter 2004 financial results two weeks from today on Thursday, November 4, 2004.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, including its recent acquisition of Sicor Inc., the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.



21 באוקטובר, 2004

טבע מודיעה כי המכירות הגלובליות של הקופקסון[®] במונחי מכירה לשוק, לרבעון השלישי, עלו ב- 34% והסתכמו ב- 242 מליון \$

טבע הודיעה היום, בהמשך לפרסום התוצאות הכספיות של שותפתה של טבע, Sanofi-Aventis, כי המכירות הגלובליות במונחי מכירה לשוק, של קופקסון[®], הסתכמו ברבעון השלישי של 2004, ב- 242 מליון \$, גידול של 34% לעומת הרבעון המקביל בשנת 2003.

המכירות בארה"ב גדלו ב-32% לעומת הרבעון השלישי של 2003 והסתכמו ב- 163 מליון \$ והמכירות מחוץ לארה"ב, בעיקר באירופה, עלו ב-39% והסתכמו ב- 79 מליון \$.

מכירות הקופקסון[®] בתשעת החודשים הראשונים של 2004, הסתכמו ב-675 מליון \$, גידול של 32% לעומת התקופה המקבילה אשתקד. המכירות בארה"ב בתקופה זו, עלו ב- 28% והסתכמו ב- 450 מליון \$ והמכירות מחוץ לארה"ב גדלו ב- 41% והסתכמו ב- 224 מליון \$.

נתח השוק של קופקסון[®], במונחים של סך כל המרשמים, בארה"ב, שוק הטרשת הנפוצה הגדול ביותר בעולם, המשיך לגדול מעבר ל- 30%, ציון הדרך שהושג ביוני 2004. ברבעון השלישי של 2004, הגיע נתח השוק של קופקסון[®] ל- 30.5% מסך כל המרשמים בשוק.

כפי שהודיעה טבע, החברה תפרסם את תוצאותיה הכספיות לרבעון השלישי של שנת 2004 בעוד שבועיים, ביום חמישי, 4 בנובמבר, 2004.

טבע תעשיות פרמצבטיות בע"מ הינה חברה גלובלית שבסיסה בישראל ואחת מ- 25 החברות הפרמצבטיות המובילות בעולם. טבע, המתמחה בייצור תרופות גנריות וייחודיות ובייצור חומרים פעילים לתעשייה הפרמצבטית, הינה אחת מהמובילות בעולם בתחום הגנריקה. לטבע אתרי ייצור, מחקר, שיווק והפצה בישראל, בצפון ומרכז אמריקה ובאירופה. קרוב ל- 90% ממכירותיה של הקבוצה הן לצפון אמריקה ואירופה.

ואשר מטרתו להגן על החברה, עפ"י הדין האמריקאי, בכל הקשור לנתונים שיש להם משמעות "Safe Harbor" להלן הסעיף הידוע בארה"ב בשם של תחזית ואשר כתוצאה מכך חשופים לסיכונים ואי ודאות:

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, including its recent acquisition of Sico Inc., the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

דורית מלצר – מנהלת קשרי משקיעים dorit.meltzer@teva.co.il
רח' בול 5 ת.ד. 3190 פתח-תקוה 49131 מל. 03-9267554 פקסימיליה 03-9267519

Web site: www.tevapharm.com